Is Dual Blockade Most Effective for CHF? When to Use ARB and ACE Inhibitors Together Christian Werner, MD; Michael Böhm, MD Disclosures Geriatrics and Aging. 2008;11 (4):223-230. 0 ...

Combined RAS blockade with ACE inhibitors and ARBs seems to be an efficient treatment option for persons with CHF Stage C and D. However, these individuals are often subject to a multimodal therapy.

While the association between the use of ACE inhibitors/ARBs and risk of contracting COVID-19 remain unclear and future virology studies are needed, these findings may inform the safety of ACEI/ARB ...

Key messages • After kidney transplantation (a surgical procedure where a kidney is transferred from one person - the donor - to another person - the recipient), it may take a few days for the kidney ...

Carrie Coon is supportive of her husband Tracy Letts' unexpected vice. During a Monday, June 16 appearance on The Tonight Show Starring Jimmy Fallon, theThe White Lotus actress, 44, spoke with ...

The presence of epithelial-mesenchymal transition (EMT) in breast cancer (BC) cells has been linked to worse prognosis and may influence response to systemic treatment. We explored the effect of EMT ...

There's nothing that ruins a good meal quite like it coming back up. The burning sensation in the chest that follows is known as heartburn, and it can happen if food or stomach acid reenters the… ...

Casein kinase 2 (CK2) has emerged as a promising therapeutic target across a broad spectrum of malignancies, including pediatric and orphan cancers. The identification of a ligandable allosteric αD ...

Concerted, urgent action is needed to improve the knowledge base and strengthen responses to gender-related killings (femicides/feminicides) and other forms of gender-based violence against women and ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Otsuka has shared positive data from its Phase III VISIONARY clinical trial (NCT05248646) of sibeprenlimab in adults with immunoglobulin A nephropathy (IgAN). The investigational monoclonal antibody ...